A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Pfizer
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
IDEAYA Biosciences
Debiopharm International SA
University of Pittsburgh
Orano Med LLC
Bayer
Beijing Biotech
A2 Biotherapeutics Inc.
Chung Shan Medical University
University of Kansas Medical Center
DualityBio Inc.
First Affiliated Hospital of Ningbo University
Calico Life Sciences LLC
SciTech Development, Inc.
Memorial Sloan Kettering Cancer Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Incyte Corporation
Shanghai Pulmonary Hospital, Shanghai, China
Second Life Therapeutics
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
Blanco, Dr Antonio Calles MD
Biogen
Shanghai Chest Hospital
University Hospital Southampton NHS Foundation Trust
A2 Biotherapeutics Inc.
Faeth Therapeutics
Biomea Fusion Inc.
Stanford University
Bristol-Myers Squibb
Sun Yat-sen University
Anaveon AG
Molecular Templates, Inc.
Dana-Farber Cancer Institute
Mundipharma Research Limited
Shanghai Pulmonary Hospital, Shanghai, China
National Cancer Institute (NCI)
Shanghai Jiao Tong University School of Medicine
Samsung Medical Center
National Cancer Institute (NCI)
Augusta University
Chang Gung Memorial Hospital
Aurigene Discovery Technologies Limited
Peking University Third Hospital
University of Kansas Medical Center
Pfizer
H. Lee Moffitt Cancer Center and Research Institute